Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14844752 | 0.87 | TGFBR1 (0.48) | THRBTGFBR1LPLLIPGMAPK14 | |
| SCHEMBL14845035 | 0.84 | TGFBR1 (0.39) | THRBTGFBR1CSNK1DCSNK1E | |
| SCHEMBL24548256 | 0.83 | LPL (0.42) | LPLLIPGCSNK1DCSNK1E | |
| SCHEMBL25224352 | 0.83 | CSNK1D (0.43) | THRBTGFBR1LPLLIPGMAPK14 | |
| SCHEMBL24554220 | 0.82 | LPL (0.41) | LPLLIPGMAPK14CSNK1DCSNK1E | |
| SCHEMBL24553855 | 0.79 | KCNK3 (0.42) | LPLLIPGCSNK1DCSNK1E | |
| SCHEMBL24547960 | 0.79 | CSNK1E (0.46) | LPLLIPGCSNK1DCSNK1E | |
| SCHEMBL26720608 | 0.79 | LPL (0.42) | LPLLIPGMAPK14CSNK1DCSNK1E | |
| SCHEMBL24553872 | 0.77 | GRM5 (0.45) | CSNK1DCSNK1E | |
| SCHEMBL24553924 | 0.77 | DRD2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763993-B1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER IP GMBH (DE) | 2017-04-19 | — | — | EP | disclosed |
| US-9314026-B2 | Heterocyclylpyri(mi)dinylpyrazole | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20140364456-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-11 | — | — | US | disclosed |
| EP-2763993-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | Bayer Intellectual Property GmbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013050434-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364456-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | H1-0, NQO2, CCNI | THRB 4167/4885TGFBR1 1833/4885LPL 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.